ATE412778T1 - Humanes fettleibigkeit suszeptibilitätsgen und deren verwendungen - Google Patents

Humanes fettleibigkeit suszeptibilitätsgen und deren verwendungen

Info

Publication number
ATE412778T1
ATE412778T1 AT03730032T AT03730032T ATE412778T1 AT E412778 T1 ATE412778 T1 AT E412778T1 AT 03730032 T AT03730032 T AT 03730032T AT 03730032 T AT03730032 T AT 03730032T AT E412778 T1 ATE412778 T1 AT E412778T1
Authority
AT
Austria
Prior art keywords
obesity
gene
diagnosis
prevention
treatment
Prior art date
Application number
AT03730032T
Other languages
English (en)
Inventor
Peter Brooks
Elke Roschmann
Anne Philippi
Joerg Hager
Original Assignee
Integragen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02291201A external-priority patent/EP1362926A1/de
Priority claimed from EP20020292392 external-priority patent/EP1403380A1/de
Application filed by Integragen Sa filed Critical Integragen Sa
Application granted granted Critical
Publication of ATE412778T1 publication Critical patent/ATE412778T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03730032T 2002-05-15 2003-05-14 Humanes fettleibigkeit suszeptibilitätsgen und deren verwendungen ATE412778T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02291201A EP1362926A1 (de) 2002-05-15 2002-05-15 Humanes fettleibigkeit Suszeptibilitätsgen und deren Verwendungen
EP20020292392 EP1403380A1 (de) 2002-09-27 2002-09-27 Humanes fettleibigkeit Suszeptibilitätsgen und deren Verwendungen

Publications (1)

Publication Number Publication Date
ATE412778T1 true ATE412778T1 (de) 2008-11-15

Family

ID=29551340

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03730032T ATE412778T1 (de) 2002-05-15 2003-05-14 Humanes fettleibigkeit suszeptibilitätsgen und deren verwendungen

Country Status (9)

Country Link
US (2) US20050123923A1 (de)
EP (3) EP1504125B1 (de)
AT (1) ATE412778T1 (de)
AU (1) AU2003240640B2 (de)
CA (1) CA2484176A1 (de)
DE (1) DE60324414D1 (de)
DK (1) DK1504125T3 (de)
ES (1) ES2314206T3 (de)
WO (1) WO2003097683A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580727A1 (en) 2004-09-17 2006-03-30 Children's Medical Center Corporation Compositions and methods for obesity screening using polymorphisms in npy2r
EP1815027A1 (de) * 2004-11-22 2007-08-08 Integragen Für kaliumionenkanäle kodierendes humanes adipositas-suszeptibilitätsgen und dessen verwendung
US20060177847A1 (en) * 2004-12-09 2006-08-10 Perlegen Sciences, Inc. Markers for metabolic syndrome obesity and insulin resistance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
WO1994019478A1 (en) 1993-02-22 1994-09-01 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
US5516653A (en) * 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
EP0791009A4 (de) * 1994-11-07 2003-03-05 Merck & Co Inc Modifizierter neuropeptid-y-rezeptor
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO2000030674A1 (en) * 1998-11-26 2000-06-02 Ferring Bv Neuropeptide y y4 agents in the treatment of reproductive disorders
WO2001018250A2 (en) * 1999-09-10 2001-03-15 Whitehead Institute For Biomedical Research Single nucleotide polymorphisms in genes

Also Published As

Publication number Publication date
EP1504125A2 (de) 2005-02-09
AU2003240640B2 (en) 2009-10-22
EP1995331A1 (de) 2008-11-26
DK1504125T3 (da) 2009-02-09
CA2484176A1 (en) 2003-11-27
DE60324414D1 (de) 2008-12-11
EP1504125B1 (de) 2008-10-29
ES2314206T3 (es) 2009-03-16
WO2003097683A2 (en) 2003-11-27
WO2003097683A3 (en) 2004-04-01
US20050123923A1 (en) 2005-06-09
EP1997913A1 (de) 2008-12-03
AU2003240640A1 (en) 2003-12-02
US20070154935A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
Carrasquillo et al. Replication of CLU, CR1, and PICALM associations with alzheimer disease
Ghani et al. Association of long runs of homozygosity with Alzheimer disease among African American individuals
Ivanova et al. Hereditary spastic paraplegia 3A associated with axonal neuropathy
EP1100547A4 (de) Zusammensetzungen und verfahren für die behandlung und diagnose von herzgefässerkrankungen.
Kuo et al. FCGR2A promoter methylation and risks for intravenous immunoglobulin treatment responses in Kawasaki disease
HRP20020093A2 (en) Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
ATE412778T1 (de) Humanes fettleibigkeit suszeptibilitätsgen und deren verwendungen
De Michele et al. Atypical Friedreich ataxia phenotype associated with a novel missense mutation in the X25 gene
WO2001081634A3 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
DE602005013080D1 (de) Für prkcb1 kodierendes humanes autismus-suszeptibilitätsgen und dessen verwendung
WO2001020026A3 (en) POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
IL179744A0 (en) Human obesity susceptibility gene encoding a potassium voltage-gated channel and uses thereof
AU7317400A (en) Transporter genes oatp-b, c, d and e
WO2005021787A3 (en) Human obesity susceptibility gene and uses thereof
ATE482290T1 (de) Ein transmembranprotein kodierendes humanes autismus-suszeptibilitätsgen und dessen verwendung
Botis et al. Cognitive function in female patients with schizophrenia and metabolic syndrome
WO2005090600A3 (en) Human obesity susceptibility genes encoding peptide hormones and uses thereof
Nicol The variation of response to pharmacotherapy: Pharmacogenetics-a new perspective to'the right drug for the right person'
WO1999045112A3 (en) Chromosome 11-linked coronary heart disease susceptibility gene chd1
Wolthers et al. Common Genetic Variants in Trypsin Regulating Genes Are Associated with AsparAginase-Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Study
Mardziah et al. Detection of BCR-ABL T315i mutation in imatinib resistant chronic myeloid leukemia patients
Martin Substance-abusing adolescents show ethnic and gender differences in psychiatric disorders
Kubarieva et al. Marketing investigation of preventive therapy of patients with multiple sclerosis
Paz-Pacheco et al. EVALUATION OF CANDIDATE GENETIC VARIATIONS AS PHARMACOGENETIC MARKERS FOR GLICLAZIDE AMONG FILIPINOS
Samson Study Suggests Learning Disabilities May Foretell Progressive Aphasia

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties